Bowel perforation in non-small cell lung cancer after bevacizumab therapy

@article{Schellhaas2008BowelPI,
  title={Bowel perforation in non-small cell lung cancer after bevacizumab therapy},
  author={Elisabeth Schellhaas and Christoph Loddenkemper and Alexander Schmittel and Heinz-J. Buhr and Uwe Pohlen},
  journal={Investigational New Drugs},
  year={2008},
  volume={27},
  pages={184-187}
}
SummaryBackground: Bevacizumab is increasingly used in combination with chemotherapy for treatment of unresectable non-small cell lung cancer. The aim of this report is to underline possible risks associated with this otherwise well-tolerated drug. Patient: A 69-year-old patient with metastatic non-small cell lung cancer was started on a palliative chemotherapy regimen containing carboplatin, paclitaxel, and bevacizumab. Results: After the second cycle of chemotherapy, the patient developed… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

FOLFOX-containing chemotherapy as a potential cause for pneumothorax.

  • Japanese journal of clinical oncology
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.

  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2007
VIEW 1 EXCERPT